Adial Pharmaceuticals (ADIL) Other financing activities (2019 - 2025)

Adial Pharmaceuticals has reported Other financing activities for 6 years, with the latest figure at $2.3 million in Q3 2025.

• Quarterly Other financing activities fell 40.67% year-over-year to $2.3 million in Q3 2025, while the trailing twelve-month figure through Sep 2025 was $9.9 million (down 10.1% YoY) and the FY2025 annual result came in at $4.8 million, up 25.9% from the prior year.
• Other financing activities retreated to $2.3 million in Q3 2025 per ADIL's latest filing, from $3.8 million in the prior quarter.
• Over five years, Other financing activities peaked at $9.1 million in Q4 2022 and troughed at -$1.4 million in Q2 2021.
• A 5-year average of $2.6 million and a median of $2.3 million in 2025 frame the typical range for Other financing activities.
• The sharpest annual moves came in 2022 and 2023: Other financing activities surged 456093900.0% in 2022, then plunged 62.91% in 2023.
• Over 5 years, Other financing activities stood at -$2.0 in 2021, then soared by 456093900.0% to $9.1 million in 2022, then slumped by 62.91% to $3.4 million in 2023, then gained by 13.04% to $3.8 million in 2024, then plunged by 40.67% to $2.3 million in 2025.
• According to Business Quant data, Other financing activities over the past three periods registered $2.3 million, $3.8 million, and $3.8 million for Q3 2025, Q3 2024, and Q1 2024 respectively.